Cantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on TG Therapeutics (NASDAQ: TGTX).The analyst comments "TGTX stock is up ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE